Clinical Trial Update: A Study of Penpulimab (AK105) in the First-line Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma [Phase 3]

View source ↗

Summary

Phase 3 clinical trial update for Penpulimab (AK105) in the first-line treatment of recurrent or metastatic nasopharyngeal carcinoma. The study is currently ACT…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Nasopharyngeal Carcinoma

Drugs mentioned

• Penpulimab (AK105) (penpulimab)

Snippet

Sponsor: Akeso | Conditions: Nasopharyngeal Carcinoma | Phase 3 | Status: ACTIVE_NOT_RECRUITING